IPO - FRACTYL HEALTH, INC.

Form Type: S-3

Filing Date: 2025-03-03

Corporate Action: Ipo

Type: New

Accession Number: 000119312525044297

Filing Summary: Fractyl Health, Inc., a metabolic therapeutics company targeting obesity and type 2 diabetes (T2D), has filed a registration statement with the SEC to offer a total of $300,000,000 in securities which includes up to $100,000,000 in common stock via a sales agreement with Jefferies LLC. The company is focused on developing therapies that durably modify the underlying causes of metabolic diseases without long-term pharmacotherapy. Their lead product, the Revita DMR System, aims to provide a solution for maintaining weight loss after discontinuation of GLP-1-based therapies. They received Breakthrough Device designation from the FDA for Revita. The company operates as a non-accelerated filer and has announced a strategic reprioritization to focus resources on the Revita program, and has paused other projects to strengthen its clinical study efforts. This is the first time the company is publicly soliciting investments through this offering, indicating an initial public offering process as a critical step in their growth strategy.

Document Link: View Document